These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 31998326)
1. Microenvironment-Dependent Gradient of CTL Exhaustion in the AE17sOVA Murine Mesothelioma Tumor Model. Hope JL; Spantidea PI; Kiernan CH; Stairiker CJ; Rijsbergen LC; van Meurs M; Brouwers-Haspels I; Mueller YM; Nelson DJ; Bradley LM; Aerts JGJV; Katsikis PD Front Immunol; 2019; 10():3074. PubMed ID: 31998326 [TBL] [Abstract][Full Text] [Related]
2. CD40 agonist converting CTL exhaustion via the activation of the mTORC1 pathway enhances PD-1 antagonist action in rescuing exhausted CTLs in chronic infection. Xu A; Wang R; Freywald A; Stewart K; Tikoo S; Xu J; Zheng C; Xiang J Biochem Biophys Res Commun; 2017 Mar; 484(3):662-667. PubMed ID: 28153727 [TBL] [Abstract][Full Text] [Related]
3. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells. Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085 [TBL] [Abstract][Full Text] [Related]
5. Plexin-A4 Mediates Cytotoxic T-cell Trafficking and Exclusion in Cancer. Celus W; Oliveira AI; Rivis S; Van Acker HH; Landeloos E; Serneels J; Cafarello ST; Van Herck Y; Mastrantonio R; Köhler A; Garg AD; Flamand V; Tamagnone L; Marine JC; Di Matteo M; Costa BM; Bechter O; Mazzone M Cancer Immunol Res; 2022 Jan; 10(1):126-141. PubMed ID: 34815265 [TBL] [Abstract][Full Text] [Related]
6. Deletion of the protein tyrosine phosphatase PTPN22 for adoptive T cell therapy facilitates CTL effector function but promotes T cell exhaustion. Teagle AR; Castro-Sanchez P; Brownlie RJ; Logan N; Kapoor SS; Wright D; Salmond RJ; Zamoyska R J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056892 [TBL] [Abstract][Full Text] [Related]
7. CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma. Wu L; Yun Z; Tagawa T; Rey-McIntyre K; de Perrot M Mol Cancer Ther; 2012 Aug; 11(8):1809-19. PubMed ID: 22584123 [TBL] [Abstract][Full Text] [Related]
8. G6PD functions as a metabolic checkpoint to regulate granzyme B expression in tumor-specific cytotoxic T lymphocytes. Lu C; Yang D; Klement JD; Colson YL; Oberlies NH; Pearce CJ; Colby AH; Grinstaff MW; Ding HF; Shi H; Liu K J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017152 [TBL] [Abstract][Full Text] [Related]
9. A Combination of Anti-PD-L1 Treatment and Therapeutic Vaccination Facilitates Improved Retroviral Clearance via Reactivation of Highly Exhausted T Cells. Knuschke T; Kollenda S; Wenzek C; Zelinskyy G; Steinbach P; Dittmer U; Buer J; Epple M; Westendorf AM mBio; 2021 Feb; 12(1):. PubMed ID: 33531395 [TBL] [Abstract][Full Text] [Related]
10. TOX-expressing terminally exhausted tumor-infiltrating CD8 Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194 [TBL] [Abstract][Full Text] [Related]
11. Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. Marzo AL; Kinnear BF; Lake RA; Frelinger JJ; Collins EJ; Robinson BW; Scott B J Immunol; 2000 Dec; 165(11):6047-55. PubMed ID: 11086036 [TBL] [Abstract][Full Text] [Related]
12. Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy. Jiang W; He Y; He W; Wu G; Zhou X; Sheng Q; Zhong W; Lu Y; Ding Y; Lu Q; Ye F; Hua H Front Immunol; 2020; 11():622509. PubMed ID: 33633741 [TBL] [Abstract][Full Text] [Related]
13. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10. Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349 [TBL] [Abstract][Full Text] [Related]
14. Immunometabolism of CD8 Shi H; Chen S; Chi H Trends Cancer; 2024 Jul; 10(7):610-626. PubMed ID: 38693002 [TBL] [Abstract][Full Text] [Related]
15. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity. Riquelme E; Carreño LJ; González PA; Kalergis AM Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198 [TBL] [Abstract][Full Text] [Related]
16. Suppression of murine tumour growth through CD8 Kogo H; Shimizu M; Negishi Y; Uchida E; Takahashi H Immunology; 2017 Jul; 151(3):324-339. PubMed ID: 28294313 [TBL] [Abstract][Full Text] [Related]
18. Novel CD8+ T cell-based vaccine stimulates Gp120-specific CTL responses leading to therapeutic and long-term immunity in transgenic HLA-A2 mice. Nanjundappa RH; Wang R; Xie Y; Umeshappa CS; Xiang J Vaccine; 2012 May; 30(24):3519-25. PubMed ID: 22484292 [TBL] [Abstract][Full Text] [Related]
19. CTL-Promoting Effects of IL-21 Counteract Murine Lupus in the Parent→F1 Graft-versus-Host Disease Model. Nguyen V; Rus H; Chen C; Rus V J Immunol; 2016 Feb; 196(4):1529-40. PubMed ID: 26792801 [TBL] [Abstract][Full Text] [Related]
20. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity. Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]